BR113 / BioRay Biopharmaceutical - LARVOL DELTA

A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=258 | Not yet recruiting | Sponsor: BioRay Pharmaceutical Co., Ltd.

First-in-human • New P1 trial • Oncology • Solid Tumor

A novel dual drug antibody-drug conjugate targeting hTrop2 has synergetic anti-tumor activity in solid tumor models (AACR 2024) - "Our findings highlight the therapeutic potential of the BiADC format for treating refractory advanced solid tumors. The outstanding anti-tumor activity across various CDX tumor models and its favorable safety profile in mice support further evaluation of the innovative BiADC, BR113."

ADC • Preclinical • Oncology • Solid Tumor